Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023
21st October 2023
Portfolio
This post references, or is about Harpoon. Find out more by clicking below
Print Article
Email Article
Save Article
